- US-listed companies
- Axsome Therapeutics, Inc.
- Income statement
Axsome Therapeutics, Inc. (AXSM) Income statement
Market cap
$12.1B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | - | - | - | - | - | - | 50 | 271 | 386 | 638 |
| Revenue growth (%) | - | - | - | - | - | - | - | |||
| Cost of revenue | - | - | - | - | - | - | 5 | 26 | 33 | 47 |
| Research & development | 21 | 20 | 23 | 54 | 70 | 58 | 58 | 98 | 187 | 183 |
| Selling, general & administrative | - | - | - | - | - | - | 159 | 323 | 411 | 571 |
| Operating margin (%) | - | - | - | - | - | - | ||||
| Operating expenses | 28 | 27 | 33 | 67 | 99 | 125 | 230 | 502 | 666 | 805 |
| Operating income | -27,543,508 | -27,164,307 | -32,846,577 | -67,245,097 | -99,141,328 | -124,706,930 | -179,799,055 | -232 | -281 | -167 |
| Income before tax | - | - | - | - | - | - | - | -238 | -287 | -184 |
| Pretax margin (%) | - | - | - | - | - | - | - | -88.1 | -74.4 | -28.8 |
| Provision for income taxes | - | - | - | - | - | - | - | 1 | 0 | -0 |
| Effective tax rate (%) | - | - | - | - | - | - | - | |||
| Net income | -27,201,653 | -28,943,392 | -30,965,464 | -68,345,186 | -102,900,600 | -130,402,992 | -187,133,651 | -239 | -287 | -183 |
| Net income margin (%) | - | - | - | - | - | - | ||||
| Earnings per share | - | - | - | - | - | - | -4.6 | -5.27 | -5.99 | -3.68 |
| Diluted EPS | - | - | - | - | - | - | -4.6 | -5.27 | -5.99 | -3.68 |